药物不良反应杂志2024,Vol.26Issue(2) :123-125.DOI:10.3760/cma.j.cn114015-20230331-00243

伏立康唑与奈玛特韦/利托那韦联用致肝损伤

Liver injury caused by the combination of voriconazole and nirmatrelvir/ritonavir

郭冬杰 李朋梅 王淑洁
药物不良反应杂志2024,Vol.26Issue(2) :123-125.DOI:10.3760/cma.j.cn114015-20230331-00243

伏立康唑与奈玛特韦/利托那韦联用致肝损伤

Liver injury caused by the combination of voriconazole and nirmatrelvir/ritonavir

郭冬杰 1李朋梅 1王淑洁
扫码查看

作者信息

  • 1. 中日友好医院药学部,北京 100029
  • 折叠

摘要

1例66岁男性肺移植术后患者,长期服用他克莫司、麦考酚钠、泼尼松三联药物抗排斥反应。因患者发生新型冠状病毒和肺部真菌感染,给予奈玛特韦/利托那韦(Paxlovid)抗病毒治疗,2 d后加用伏立康唑抗真菌治疗。加用伏立康唑前患者丙氨酸转氨酶34 U/L,天冬氨酸转氨酶28 U/L。伏立康唑与Paxlovid联用第4天,伏立康唑血药谷浓度16.06 mg/L,丙氨酸转氨酶176 U/L,天冬氨酸转氨酶166 U/L,立即停用伏立康唑,2 d后停用Paxlovid。伏立康唑停药5 d后,患者肝功能恢复正常;9 d后,其血药谷浓度为5.84 mg/L。考虑患者的肝损伤是伏立康唑与Paxlovid联用所致。 A 66-year-old male patient who underwent lung transplantation took a combination therapy with tacrolimus, mycophenolate sodium, and prednisone for a long time to resist rejection.Due to the occurrence of novel coronavirus and pulmonary fungal infection,the patient was given antiviral therapy with nirmatrelvir/ritonavir (Pavlovid), followed by antifungal therapy with voriconazole 2 days later. Before voriconazole treatment, the patient′s alanine aminotransferase was 34 U/L, and aspartate aminotransferase was 28 U/L. On the 4th day of the combination of voriconazole and Paxlovid, the patient′s blood trough concentration of voriconazole was 16.06 mg/L, alanine aminotransferase was 176 U/L, and aspartate amino- transferase was 166 U/L. Voriconazole was discontinued immediately and 2 days later,Paxlovid was discontinued. Five days after discontinuation of voriconazole, the patient′s liver function returned to normal 9 days later, blood trough concentration of voriconazole was 5.84 mg/L. It was considered that the patient′s liver injury was caused by the combination of voriconazole and Paxlovid.

Abstract

A 66-year-old male patient who underwent lung transplantation took a combination therapy with tacrolimus, mycophenolate sodium, and prednisone for a long time to resist rejection.Due to the occurrence of novel coronavirus and pulmonary fungal infection,the patient was given antiviral therapy with nirmatrelvir/ritonavir (Pavlovid), followed by antifungal therapy with voriconazole 2 days later. Before voriconazole treatment, the patient′s alanine aminotransferase was 34 U/L, and aspartate aminotransferase was 28 U/L. On the 4th day of the combination of voriconazole and Paxlovid, the patient′s blood trough concentration of voriconazole was 16.06 mg/L, alanine aminotransferase was 176 U/L, and aspartate amino- transferase was 166 U/L. Voriconazole was discontinued immediately and 2 days later,Paxlovid was discontinued. Five days after discontinuation of voriconazole, the patient′s liver function returned to normal 9 days later, blood trough concentration of voriconazole was 5.84 mg/L. It was considered that the patient′s liver injury was caused by the combination of voriconazole and Paxlovid.

关键词

抗病毒药/抗真菌药/化学及药物性肝损伤/伏立康唑/药物相互作用/肺移植/利托那韦/奈玛特韦

Key words

Antiviral agents/Antifungal agents/Chemical and drug induced liver injury/Voriconazole/Drug interactions/Lung transplantation/Ritonavir/Nirmatrelvir

引用本文复制引用

基金项目

国家重点研发计划(2020YFC2005504)

出版年

2024
药物不良反应杂志
中华医学会

药物不良反应杂志

CSTPCDCSCD
影响因子:0.667
ISSN:1008-5734
参考文献量14
段落导航相关论文